oxiracetam

10/01/2017 - "This study was to investigate the effects of preconditioning with Oxiracetam or fastigial nucleus stimulation (FNS) on cognitive decline following the ascension to high altitude. "
12/30/2016 - "In this study, we used behavioural methods, electrophysiology, biochemistry, histopathological staining and transmission electron microscope to investigate rat's cognitive impairment by CCH, and found that Oxiracetam could improve CCH-induced cognitive impairment and prevent deficits of neural plasticity, white matter lesions, and synaptic ultrastructure. "
01/01/2023 - "TBI mice treated with oxiracetam had a smaller decrease in preference and more latency time than those not treated with oxiracetam, suggesting the amelioration of impaired cognitive impairment. "
01/01/2023 - "Oxiracetam may have a modest effect on preventing cognitive decline. "
01/01/2023 - "Efficacy and safety of oxiracetam in patients with vascular cognitive impairment: A multicenter, randomized, double-blinded, placebo-controlled, phase IV clinical trial."

01/01/1987 - "In conclusion, in the present population of patients with mild to moderate degree dementia, 1600 mg/day of oxiracetam was effective in enhancing both attentional activities and other, more complex, neuropsychological functions."
09/01/1992 - "Oxiracetam in dementia: a double-blind, placebo-controlled study."
01/01/1987 - "40 out-patients with a mild to moderate degree of dementia (11 less than or equal to MMSE less than 24) participated in a between-subjects (n = 20 + 20) double-blind placebo-controlled randomized trial comparing the effects of oxiracetam 800 mg bid and placebo during 90 days of treatment. "
01/01/1987 - "Clinical and neuropsychological study with oxiracetam versus placebo in patients with mild to moderate dementia."
10/28/2023 - "(S)-oxiracetam is the major active enantiomer of oxiracetam, which is being developed for dementia. "

01/01/2018 - "S-oxiracetam ameliorates ischemic stroke induced neuronal apoptosis through up-regulating α7 nAChR and PI3K / Akt / GSK3β signal pathway in rats."
11/01/2014 - "This study aimed to investigate the combination effects of bone marrow stromal cells (BMSCs) and oxiracetam for ischemic stroke. "
04/01/2021 - "S-oxiracetam Facilitates Cognitive Restoration after Ischemic Stroke by Activating α7nAChR and the PI3K-Mediated Pathway."
11/15/2017 - "S-oxiracetam protect against ischemic stroke via alleviating blood brain barrier dysfunction in rats."
11/01/2014 - "Bone marrow stromal cells combined with oxiracetam influences the expression of B-cell lymphoma 2 in rats with ischemic stroke."

01/01/1989 - "Oxiracetam in the treatment of primary degenerative and multi-infarct dementia: a double-blind, placebo-controlled study."
01/01/1989 - "Oxiracetam in the treatment of multi-infarct dementia."
01/01/1989 - "2. Because previous studies had not specifically examined the effects of oxiracetam upon dementias of vascular origin, the present study evaluated the therapeutic efficacy and safety of oxiracetam in the treatment of symptoms of multi-infarct dementia (MID) of mild to moderate severity. "
01/01/1992 - "Clinical studies with oxiracetam in patients with dementia of Alzheimer type and multi-infarct dementia of mild to moderate degree."
01/01/1989 - "Oxiracetam in the treatment of multi-infarct dementia and primary degenerative dementia."

08/01/2021 - "Taken together, it is concluded that Oxiracetam reduced the expansion of ischemic infarction in part via regulating the interplay between microglia activation and autophagy, which would delay the progression of HIBD and effectively prolong the time window for the clinical treatment of HIBD."
08/01/2021 - "We demonstrated for the first time that in the acute phase of HIBD in neonatal mice, treatment of Oxiracetam (ORC) significantly curtailed the size of ischemic penumbra together with drastic reduction of infarction. "
08/05/2019 - "When compared with BMSCs or oxiracetam monotherapy, combination therapy significantly improved functional restoration with decreased infarct volume in observed ischemic brain. "
01/01/1989 - "A multicentre, double-blind, between-patient study was carried out to evaluate the efficacy and tolerability of oxiracetam (800-mg tablets), in comparison with placebo, each given twice daily for 12 weeks to patients suffering from primary degenerative, multi-infarct or mixed forms of dementia. "
09/01/1992 - "A multicentre, double-blind, between-patient study was carried out to evaluate the efficacy and tolerability of oxiracetam (800 mg tablet), in comparison with placebo, each given twice daily for 12 weeks to patients suffering from primary degenerative, multi-infarct or mixed dementia. "